Tuesday, January 11, 2011 5:42:57 PM
CLDX ($3.87) Some DD
About Celldex
Celldex Therapeutics is the first antibody-based combination immunotherapy company. Celldex has a pipeline of drug candidates in development for the treatment of cancer and other difficult-to-treat diseases based on its antibody focused Precision Targeted Immunotherapy Platform. The PTI Platform is a complementary portfolio of monoclonal antibodies, antibody-targeted vaccines and immunomodulators used in optimal combinations to create novel disease-specific drug candidates.
"Seattle Genetics (Nasdaq: SGEN) now has 10 ADC collaborations with companies as small as Celldex Therapeutics (Nasdaq: CLDX)"
http://www.fool.com/investing/high-growth/2011/01/06/145-million-down-billions-to-go.aspx
November 20th PR
APC Targeting Technology™
Project Pipeline
One of the main parts: Our deep product pipeline consists of products in varying stages of development, with lead candidate rindopepimut (CDX-110) currently undergoing evaluation in a Phase 2 clinical trial in newly diagnosed glioblastoma multiforme, one of the most aggressive forms of brain cancer.
About Celldex
Celldex Therapeutics is the first antibody-based combination immunotherapy company. Celldex has a pipeline of drug candidates in development for the treatment of cancer and other difficult-to-treat diseases based on its antibody focused Precision Targeted Immunotherapy Platform. The PTI Platform is a complementary portfolio of monoclonal antibodies, antibody-targeted vaccines and immunomodulators used in optimal combinations to create novel disease-specific drug candidates.
"Seattle Genetics (Nasdaq: SGEN) now has 10 ADC collaborations with companies as small as Celldex Therapeutics (Nasdaq: CLDX)"
http://www.fool.com/investing/high-growth/2011/01/06/145-million-down-billions-to-go.aspx
November 20th PR
APC Targeting Technology™
Project Pipeline
One of the main parts: Our deep product pipeline consists of products in varying stages of development, with lead candidate rindopepimut (CDX-110) currently undergoing evaluation in a Phase 2 clinical trial in newly diagnosed glioblastoma multiforme, one of the most aggressive forms of brain cancer.
Z-Man15 Stocks
http://investorshub.advfn.com/boards/board.aspx?board_id=18695
The "Q" and Low Float Reverse Merger Team
http://investorshub.advfn.com/boards/board.aspx?board_id=18436
Discover What Traders Are Watching
Explore small cap ideas before they hit the headlines.
